Global Artificial Intellgence (AI) LPartnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018

The Global Artificial Intelligence (AI) LPartnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018 report provides an understanding and access to the Artificial Intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Artificial Intelligence partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Artificial Intelligence partnering contract documents
Top Artificial Intelligence deals by value

The Global Artificial Intelligence Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides an understanding and access to the Artificial Intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Artificial Intelligence partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Artificial Intelligence technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Artificial Intelligence agreements announced in the healthcare sectors, covering:

Artificial Intelligence
AI
Machine learning

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Artificial Intelligence deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Artificial Intelligence dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Artificial Intelligence dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Artificial Intelligence deals since 2010. Deals are listed by headline value, signed by big pharma, most active Artificial Intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Artificial Intelligence dealmaking with a brief summary followed by a comprehensive listing of Artificial Intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Artificial Intelligence partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Artificial Intelligence partnering deals signed and announced since Jan 2010. The chapter is organized by specific Artificial Intelligence technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Artificial Intelligence partnering company A-Z, deal type definitions and Artificial Intelligence partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Artificial Intelligence partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Artificial Intelligence technologies and products.

Report scope

Global Artificial Intelligence Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018 is intended to provide the reader with an in-depth understanding and access to Artificial Intelligence trends and structure of deals entered into by leading companies worldwide.

Global Artificial Intelligence Partnering Terms and Agreements 2010 to 2018 includes:

Trends in Artificial Intelligence dealmaking in the biopharma industry since 2010
Analysis of Artificial Intelligence deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Artificial Intelligence deals
Access to over 200 Artificial Intelligence deal records and contract documents where available
The leading antibody deals by value since 2010
Most active Artificial Intelligence dealmakers since 2010
The leading Artificial Intelligence partnering resources

In GlobalArtificial Intelligence Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2018, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Artificial Intelligence dealmaking

2.1. Introduction
2.2. Artificial Intelligence partnering over the years
2.3. Most active Artificial Intelligence dealmakers
2.4. Artificial Intelligence partnering by deal type
2.5. Artificial Intelligence partnering by therapy area
2.6. Artificial Intelligence partnering by industry sector
2.7. Deal terms for Artificial Intelligence partnering
2.7.1 Artificial Intelligence partnering headline values
2.7.2 Artificial Intelligence deal upfront payments
2.7.3 Artificial Intelligence deal milestone payments
2.7.4 Artificial Intelligence royalty rates
2.8. The anatomy of an Artificial Intelligence deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 Leading Artificial Intelligence deals

3.1. Introduction
3.2. Top Artificial Intelligence deals by value

Chapter 4 Most active Artificial Intelligence dealmakers

4.1. Introduction
4.2. Most active Artificial Intelligence dealmakers
4.3. Most active Artificial Intelligence partnering company profiles

Chapter 5 Artificial Intelligence contracts dealmaking directory

5.1. Introduction
5.2. Artificial Intelligence contracts dealmaking directory

Chapter 6 Artificial Intelligence dealmaking by technology type

Chapter 7 Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 Artificial Intelligence deals by company A-Z
Appendix 2 Artificial Intelligence deals by stage of development
Appendix 3 Artificial Intelligence deals by deal type
Appendix 4 Artificial Intelligence deals by therapy area
Appendix 5 Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Artificial Intelligence partnering since 2010
Figure 2: Active Artificial Intelligence dealmaking activity sincce 2010
Figure 3: Artificial Intelligence partnering by deal type since 2010
Figure 4: Artificial Intelligence partnering by disease type since 2010
Figure 5: Artificial Intelligence partnering by industry sector since 2010
Figure 6: Artificial Intelligence deals with a headline value
Figure 7: Artificial Intelligence deals with an upfront value
Figure 8: Artificial Intelligence deals with a milestone value
Figure 9: Artificial Intelligence deals with a royalty rate value
Figure 10: Top Artificial Intelligence deals by value since 2010
Figure 11: Most active Artificial Intelligence dealmakers since 2010
Figure 12: Artificial Intelligence partnering by technology type since 2010
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events

Global Avascular Necrosis Market Research Report - Forecast to 2024

IntroductionAvascular necrosis is the death of the bone tissue due to a lack of blood supply and is also known as osteonecrosis. Avascular necrosis can lead to tiny breaks in

USD 4450 View Report

2018 Global Thrombin Time Market: US, Europe, Japan--Volume and Sales Segmentation Forecasts, Competitive Landscape, Current Methods and Instrumentation, Opportunities for Suppliers

The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next five years. New specific and sensitive markers of

USD 3450 View Report

Global Artificial Heart-lung Machine Market Research Report 2018

Artificial Heart-lung Machine Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on

USD 2850 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available